grp94 in 2

EPZ032597 is a novel selective inhibitor of SMYD2 with an IC50 of 16 nM. EPZ032597 has anticancer activity and can be used to prevent and treat pancreatic cancer.

Grp94 Inhibitor-2 (compound 23) is a cyclopropane analog that exhibits high affinity for Glucose Regulated Protein 94 (Grp94), with dissociation constants (Kd) of 0.48 µM for Grp94 and 0.65 µM for Hsp90α.

Grp94-IN-2 is a inhibitor of Grp94.

4-Br-Bnlm, with an EC 50 of 0.96 µM, acts as a selective inhibitor of glucose-regulated protein 94 (Grp94). It effectively reduces both mutant and wild-type misfolded myocilin proteins in cells, thereby enhancing the clearance of toxic forms of myocilin and diminishing myocilin toxicity [1] [2].